Skip to main content
Erschienen in: Drugs & Aging 7/2019

04.05.2019 | Current Opinion

Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly

verfasst von: Erminia Ridolo, P. Kihlgren, I. Pellicelli, M. C. Nizi, F. Pucciarini, C. Incorvaia

Erschienen in: Drugs & Aging | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Among the different forms of allergic conjunctivitis, atopic keratoconjunctivitis has distinct characteristics, defined by a more common onset in late adolescence or early adulthood, but also affecting the elderly, and with a higher prevalence in male individuals. However, the prevalence of atopic keratoconjunctivitis is scarcely investigated, and the data are often uncertain because other allergic nasal or respiratory disorders occur concomitantly. Mast cells, eosinophils, basophils, and T cells are involved in the pathogenesis of atopic keratoconjunctivitis. Despite its denomination as atopic, negative responses to skin tests or in-vitro immunoglobulin E tests are common. In fact, atopic keratoconjunctivitis can be attributed to a combination of T-helper-1 and T-helper-2 responses, but a higher prominence for T-helper-1 cells was found. The most common symptoms of atopic keratoconjunctivitis are bilateral ocular itching, burning, and tearing with a perennial presentation, although some patients may have seasonal exacerbations in winter or summer. Other symptoms such as photophobia, blurred vision, and mucous chewy discharge, owing to the accumulation of cells and mucin, may occur. The diagnosis of atopic keratoconjunctivitis is mainly clinical, as accepted diagnostic criteria or laboratory tests are not available. The treatment of atopic keratoconjunctivitis is aimed at controlling symptoms, decreasing relapse and exacerbations, and reducing vision loss. Therapeutic options comprise topical ophthalmic drops, including cromones, antihistamines, corticosteroids, and calcineurin inhibitors. Topical ointments are also available for corticosteroids and calcineurin inhibitors. Severe forms may require systemic medications including antihistamines, corticosteroids, and calcineurin inhibitors. Atopic keratoconjunctivitis therapy in the elderly does not differ from the adult population, but the occurrence of multi-morbidities and concomitant drug treatment, which are common in this age group, requires a careful evaluation to determine appropriate and personalized treatment.
Literatur
2.
Zurück zum Zitat Bonini S, Gramiccioni C, Bonini M, Bresciani M. Practical approach to diagnosis and treatment of ocular allergy: a 1-year systematic review. Curr Opin Allergy Clin Immunol. 2007;7(5):446–9.CrossRefPubMed Bonini S, Gramiccioni C, Bonini M, Bresciani M. Practical approach to diagnosis and treatment of ocular allergy: a 1-year systematic review. Curr Opin Allergy Clin Immunol. 2007;7(5):446–9.CrossRefPubMed
3.
Zurück zum Zitat Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: a review. J Am Acad Dermatol. 2014;70(3):569–75.CrossRefPubMed Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: a review. J Am Acad Dermatol. 2014;70(3):569–75.CrossRefPubMed
4.
Zurück zum Zitat Yoneda K, Okamoto H, Wada Y, Morita K, Takahashi M, Ogura Y, et al. Atopic retinal detachment: report of four cases and a review of the literature. Br J Dermatol. 1995;133(4):586–91.CrossRefPubMed Yoneda K, Okamoto H, Wada Y, Morita K, Takahashi M, Ogura Y, et al. Atopic retinal detachment: report of four cases and a review of the literature. Br J Dermatol. 1995;133(4):586–91.CrossRefPubMed
5.
Zurück zum Zitat Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988–1994. J Allergy Clin Immunol. 2010;126(4):778–83.CrossRefPubMed Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988–1994. J Allergy Clin Immunol. 2010;126(4):778–83.CrossRefPubMed
6.
Zurück zum Zitat Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol. 2000;06(6):1019–32.CrossRef Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol. 2000;06(6):1019–32.CrossRef
7.
8.
Zurück zum Zitat Trocme SD, Bonini S, Barney NP, Bloch KJ, Allansmith MR. Late-phase reaction in topically induced ocular anaphylaxis in the rat. Curr Eye Res. 1988;7(5):437–43.CrossRefPubMed Trocme SD, Bonini S, Barney NP, Bloch KJ, Allansmith MR. Late-phase reaction in topically induced ocular anaphylaxis in the rat. Curr Eye Res. 1988;7(5):437–43.CrossRefPubMed
9.
Zurück zum Zitat Oshinskie L, Haine C. Atopic dermatitis and its ophthalmic complications. J Am Optom Assoc. 1982;53(11):889–94.PubMed Oshinskie L, Haine C. Atopic dermatitis and its ophthalmic complications. J Am Optom Assoc. 1982;53(11):889–94.PubMed
10.
Zurück zum Zitat Rich LF, Hanifin JM. Ocular complications of atopic dermatitis and other eczemas. Int Ophthalmol Clin. 1985;25(1):61–76.CrossRefPubMed Rich LF, Hanifin JM. Ocular complications of atopic dermatitis and other eczemas. Int Ophthalmol Clin. 1985;25(1):61–76.CrossRefPubMed
11.
Zurück zum Zitat Uchio E, Ono SY, Ikezawa Z, Ohno S. Tear levels of interferon-gamma, interleukin (IL)-2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin Exp Allergy. 2000;30(1):103–9.CrossRefPubMed Uchio E, Ono SY, Ikezawa Z, Ohno S. Tear levels of interferon-gamma, interleukin (IL)-2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin Exp Allergy. 2000;30(1):103–9.CrossRefPubMed
12.
Zurück zum Zitat Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2010;10(5):478–85.CrossRefPubMed Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2010;10(5):478–85.CrossRefPubMed
13.
Zurück zum Zitat Calder VL, Jolly G, Hingorani M, et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy. 1999;29(9):1214–22.CrossRefPubMed Calder VL, Jolly G, Hingorani M, et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy. 1999;29(9):1214–22.CrossRefPubMed
14.
Zurück zum Zitat Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol. 2007;7(5):429–35.CrossRefPubMed Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol. 2007;7(5):429–35.CrossRefPubMed
16.
Zurück zum Zitat Nivenius E, Van der Ploeg I, Gafvelin G, et al. Conjunctival provocation with airborne allergen in patients with atopic keratoconjunctivitis. Clin Exp Allergy. 2012;42(1):58–65.CrossRefPubMed Nivenius E, Van der Ploeg I, Gafvelin G, et al. Conjunctival provocation with airborne allergen in patients with atopic keratoconjunctivitis. Clin Exp Allergy. 2012;42(1):58–65.CrossRefPubMed
17.
Zurück zum Zitat Bielory L. Atopic dermatitis and keratoconjunctivitis. Immunol Allergy Clin N Am. 2010;30(3):323–36.CrossRef Bielory L. Atopic dermatitis and keratoconjunctivitis. Immunol Allergy Clin N Am. 2010;30(3):323–36.CrossRef
18.
Zurück zum Zitat Metz DP, Hingorani M, Calder VL, Buckley RJ, Lightman SL. T-cell cytokines in chronic allergic eye disease. J Allergy Clin Immunol. 1997;100(6 Pt 1):817–24.CrossRefPubMed Metz DP, Hingorani M, Calder VL, Buckley RJ, Lightman SL. T-cell cytokines in chronic allergic eye disease. J Allergy Clin Immunol. 1997;100(6 Pt 1):817–24.CrossRefPubMed
20.
Zurück zum Zitat Lin J, Zhao GQ, Wang Q, et al. Regulation of interleukin 33/ST2 signaling of human corneal epithelium in allergic diseases. Int J Ophthalmol. 2013;6:23–9.PubMedPubMedCentral Lin J, Zhao GQ, Wang Q, et al. Regulation of interleukin 33/ST2 signaling of human corneal epithelium in allergic diseases. Int J Ophthalmol. 2013;6:23–9.PubMedPubMedCentral
21.
Zurück zum Zitat Leonardi A, Jose PJ, Zhan H, Calder VL. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology. 2003;110(3):487–92.CrossRefPubMed Leonardi A, Jose PJ, Zhan H, Calder VL. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology. 2003;110(3):487–92.CrossRefPubMed
22.
Zurück zum Zitat Yamagami S, Ebihara N, Amano SY. Chemokine receptor gene expression in giant papillae of atopic keratoconjunctivitis. Mol Vis. 2005;11:192–200.PubMed Yamagami S, Ebihara N, Amano SY. Chemokine receptor gene expression in giant papillae of atopic keratoconjunctivitis. Mol Vis. 2005;11:192–200.PubMed
23.
Zurück zum Zitat Kitaichi N, Shimizu T, Honda A, et al. Increase in macrophage migration inhibitory factor levels in lacrimal fluid of patients with severe atopic dermatitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(7):825–8.CrossRefPubMed Kitaichi N, Shimizu T, Honda A, et al. Increase in macrophage migration inhibitory factor levels in lacrimal fluid of patients with severe atopic dermatitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(7):825–8.CrossRefPubMed
24.
Zurück zum Zitat Yasuda C, Enomoto A, Ishiwatari S, et al. Macrophage migration inhibitory factor (MIF) in the stratum corneum: a marker of the local severity of atopic dermatitis. Exp Dermatol. 2014;23(10):764–6.CrossRefPubMed Yasuda C, Enomoto A, Ishiwatari S, et al. Macrophage migration inhibitory factor (MIF) in the stratum corneum: a marker of the local severity of atopic dermatitis. Exp Dermatol. 2014;23(10):764–6.CrossRefPubMed
25.
Zurück zum Zitat Zhan H, Smith L, Calder V, Buckley R, Lightman S. Clinical and immunological features of atopic keratoconjunctivitis. Int Ophthalmol Clin. 2003;43(1):59–71.CrossRefPubMed Zhan H, Smith L, Calder V, Buckley R, Lightman S. Clinical and immunological features of atopic keratoconjunctivitis. Int Ophthalmol Clin. 2003;43(1):59–71.CrossRefPubMed
26.
Zurück zum Zitat Tuft SJ, Ramakrishnan M, Seal DV, Kemeny DM, Buckley RJ. Role of Staphylococcus aureus in chronic allergic conjunctivitis. Ophthalmology. 1992;99(2):180–4.CrossRefPubMed Tuft SJ, Ramakrishnan M, Seal DV, Kemeny DM, Buckley RJ. Role of Staphylococcus aureus in chronic allergic conjunctivitis. Ophthalmology. 1992;99(2):180–4.CrossRefPubMed
27.
Zurück zum Zitat Dogru M, Nakagawa N, Tetsumoto K, Katakami C, Yamamoto M. Ocular surface disease in atopic dermatitis. Jpn J Ophthalmol. 1999;43(1):53–7.CrossRefPubMed Dogru M, Nakagawa N, Tetsumoto K, Katakami C, Yamamoto M. Ocular surface disease in atopic dermatitis. Jpn J Ophthalmol. 1999;43(1):53–7.CrossRefPubMed
28.
Zurück zum Zitat Leonardi A, Borghesan F, Faggian D, Depaoli M, Secchi AG, Plebani M. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol. 2000;129(2):151–8.CrossRefPubMed Leonardi A, Borghesan F, Faggian D, Depaoli M, Secchi AG, Plebani M. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol. 2000;129(2):151–8.CrossRefPubMed
29.
Zurück zum Zitat Tanaka M, Dogru M, Takano Y, et al. The relation of conjunctival and corneal findings in severe ocular allergies. Cornea. 2004;23(5):464–7.CrossRefPubMed Tanaka M, Dogru M, Takano Y, et al. The relation of conjunctival and corneal findings in severe ocular allergies. Cornea. 2004;23(5):464–7.CrossRefPubMed
30.
Zurück zum Zitat Easty D, Entwistle C, Funk A, Witcher J. Herpes simplex keratitis and keratoconus in the atopic patient: a clinical and immunological study. Trans Ophthalmol Soc U K. 1975;95(2):267–76.PubMed Easty D, Entwistle C, Funk A, Witcher J. Herpes simplex keratitis and keratoconus in the atopic patient: a clinical and immunological study. Trans Ophthalmol Soc U K. 1975;95(2):267–76.PubMed
32.
Zurück zum Zitat Spergel JM. Immunology and treatment of atopic dermatitis. Am J Clin Dermatol. 2008;9(4):233–44.CrossRefPubMed Spergel JM. Immunology and treatment of atopic dermatitis. Am J Clin Dermatol. 2008;9(4):233–44.CrossRefPubMed
33.
Zurück zum Zitat Wakamatsu TH, Okada N, Kojima T, Matsumoto Y, Ibrahim OM, Dogru M, et al. Evaluation of conjunctival inflammatory status by confocal scanning laser microscopy and conjunctival brush cytology in patients with atopic keratoconjunctivitis (AKC). Mol Vis. 2009;15:1611–9.PubMedPubMedCentral Wakamatsu TH, Okada N, Kojima T, Matsumoto Y, Ibrahim OM, Dogru M, et al. Evaluation of conjunctival inflammatory status by confocal scanning laser microscopy and conjunctival brush cytology in patients with atopic keratoconjunctivitis (AKC). Mol Vis. 2009;15:1611–9.PubMedPubMedCentral
34.
Zurück zum Zitat Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352.CrossRefPubMed Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352.CrossRefPubMed
35.
Zurück zum Zitat Cardona V, Guilarte M, Luengo O, Labrador-Horrillo M, Sala-Cunill A, Garriga T. Allergic diseases in the elderly. Clin Transl Allergy. 2011;1(1):11.CrossRefPubMedPubMedCentral Cardona V, Guilarte M, Luengo O, Labrador-Horrillo M, Sala-Cunill A, Garriga T. Allergic diseases in the elderly. Clin Transl Allergy. 2011;1(1):11.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging. 1998;12(6):485–94.CrossRefPubMed Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging. 1998;12(6):485–94.CrossRefPubMed
37.
Zurück zum Zitat Shaker M, Salcone E. An update on ocular allergy. Curr Opin Allergy Clin Immunol. 2016;16(5):505–10.CrossRefPubMed Shaker M, Salcone E. An update on ocular allergy. Curr Opin Allergy Clin Immunol. 2016;16(5):505–10.CrossRefPubMed
38.
Zurück zum Zitat Simons FE, Fraser TG, Maher J, Pillay N, Simons KJ. Central nervous system effects of H1-receptor antagonists in the elderly. Ann Allergy Asthma Iimmunol. 1999;82(2):157–60.CrossRef Simons FE, Fraser TG, Maher J, Pillay N, Simons KJ. Central nervous system effects of H1-receptor antagonists in the elderly. Ann Allergy Asthma Iimmunol. 1999;82(2):157–60.CrossRef
39.
Zurück zum Zitat Breton G, Froissart M, Janus N, et al. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function: the three-city population-based study. Nephrol Dial Transplant. 2011;26(9):2852–9.CrossRefPubMedPubMedCentral Breton G, Froissart M, Janus N, et al. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function: the three-city population-based study. Nephrol Dial Transplant. 2011;26(9):2852–9.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med. 2002;113(Suppl. 9A):38s–46s.CrossRefPubMed Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med. 2002;113(Suppl. 9A):38s–46s.CrossRefPubMed
41.
42.
Zurück zum Zitat Bousquet J, Ansotegui I, Canonica GW, et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012;28(1):131–9.CrossRefPubMed Bousquet J, Ansotegui I, Canonica GW, et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012;28(1):131–9.CrossRefPubMed
43.
Zurück zum Zitat Sologuren A, Vinas R, Cordon E, et al. Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria. Allergy Asthma Proc. 2018;39(4):299–304.CrossRefPubMed Sologuren A, Vinas R, Cordon E, et al. Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria. Allergy Asthma Proc. 2018;39(4):299–304.CrossRefPubMed
44.
Zurück zum Zitat Mullol J, Bousquet J, Bachert C, et al. Update on rupatadine in the management of allergic disorders. Allergy. 2015;70(Suppl. 100):1–24.CrossRefPubMed Mullol J, Bousquet J, Bachert C, et al. Update on rupatadine in the management of allergic disorders. Allergy. 2015;70(Suppl. 100):1–24.CrossRefPubMed
45.
46.
Zurück zum Zitat Bielory L, Schoenberg D. Emerging therapeutics for ocular surface disease. Curr Allergy Asthma Rep. 2019;19(3):16.CrossRefPubMed Bielory L, Schoenberg D. Emerging therapeutics for ocular surface disease. Curr Allergy Asthma Rep. 2019;19(3):16.CrossRefPubMed
47.
Zurück zum Zitat Attas-Fox L, Barkana Y, Iskhakov V, et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res. 2008;33(7):545–9.CrossRefPubMed Attas-Fox L, Barkana Y, Iskhakov V, et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res. 2008;33(7):545–9.CrossRefPubMed
48.
Zurück zum Zitat Flammiger A, Maibach H. Drug dosage in the elderly: dermatological drugs. Drugs Aging. 2006;23(3):203–15.CrossRefPubMed Flammiger A, Maibach H. Drug dosage in the elderly: dermatological drugs. Drugs Aging. 2006;23(3):203–15.CrossRefPubMed
49.
Zurück zum Zitat Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology. 1996;47(6):1396–402.CrossRefPubMed Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology. 1996;47(6):1396–402.CrossRefPubMed
50.
Zurück zum Zitat Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Int Med. 2002;17(9):717–20.CrossRef Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Int Med. 2002;17(9):717–20.CrossRef
51.
Zurück zum Zitat Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009;116(4):652–7.CrossRefPubMed Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009;116(4):652–7.CrossRefPubMed
52.
Zurück zum Zitat Weinstein RS. Clinical practice: glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62–70.CrossRefPubMed Weinstein RS. Clinical practice: glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62–70.CrossRefPubMed
53.
Zurück zum Zitat Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord. 1983;5(4):319–32.CrossRefPubMed Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord. 1983;5(4):319–32.CrossRefPubMed
54.
Zurück zum Zitat Hall RC, Popkin MK, Stickney SK, Gardner ER. Presentation of the steroid psychoses. J Nerv Ment Dis. 1979;167(4):229–36.CrossRefPubMed Hall RC, Popkin MK, Stickney SK, Gardner ER. Presentation of the steroid psychoses. J Nerv Ment Dis. 1979;167(4):229–36.CrossRefPubMed
55.
Zurück zum Zitat Ezeamuzie CI. Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. Int J Iimmunopharmacol. 1996;18(4):263–70.CrossRef Ezeamuzie CI. Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. Int J Iimmunopharmacol. 1996;18(4):263–70.CrossRef
56.
Zurück zum Zitat Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol. 2006;90(4):461–4.CrossRefPubMedPubMedCentral Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol. 2006;90(4):461–4.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Tesse R, Spadavecchia L, Fanelli P, et al. Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children. Pediatr Allergy Immunol. 2010;21(2 Pt 1):330–5.CrossRefPubMed Tesse R, Spadavecchia L, Fanelli P, et al. Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children. Pediatr Allergy Immunol. 2010;21(2 Pt 1):330–5.CrossRefPubMed
58.
Zurück zum Zitat Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998;105(9):1715–20.CrossRefPubMed Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998;105(9):1715–20.CrossRefPubMed
59.
Zurück zum Zitat Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46(2):228–41.CrossRefPubMed Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46(2):228–41.CrossRefPubMed
60.
Zurück zum Zitat Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology. 2008;115(6):988-92.e5.CrossRef Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology. 2008;115(6):988-92.e5.CrossRef
61.
Zurück zum Zitat Hoang-Xuan T, Prisant O, Hannouche D, Robin H. Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology. 1997;104(8):1300–5.CrossRefPubMed Hoang-Xuan T, Prisant O, Hannouche D, Robin H. Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology. 1997;104(8):1300–5.CrossRefPubMed
62.
Zurück zum Zitat Stumpf T, Luqmani N, Sumich P, Cook S, Tole D. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea. 2006;25(10):1147–9.CrossRefPubMed Stumpf T, Luqmani N, Sumich P, Cook S, Tole D. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea. 2006;25(10):1147–9.CrossRefPubMed
64.
Zurück zum Zitat Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–32.CrossRefPubMed Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–32.CrossRefPubMed
66.
Zurück zum Zitat Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148:500–9.CrossRefPubMedPubMedCentral Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148:500–9.CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat Galor A, Jabs DA, Leder HA. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115(10):1826–32.CrossRefPubMed Galor A, Jabs DA, Leder HA. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115(10):1826–32.CrossRefPubMed
68.
Zurück zum Zitat Hornbeak DM, Thorne JE. Immunosuppressive therapy for eye diseases: effectiveness, safety, side effects and their prevention. Taiwan J Ophthalmol. 2015;5(4):156–63.CrossRefPubMedPubMedCentral Hornbeak DM, Thorne JE. Immunosuppressive therapy for eye diseases: effectiveness, safety, side effects and their prevention. Taiwan J Ophthalmol. 2015;5(4):156–63.CrossRefPubMedPubMedCentral
Metadaten
Titel
Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly
verfasst von
Erminia Ridolo
P. Kihlgren
I. Pellicelli
M. C. Nizi
F. Pucciarini
C. Incorvaia
Publikationsdatum
04.05.2019
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 7/2019
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-019-00676-7

Weitere Artikel der Ausgabe 7/2019

Drugs & Aging 7/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.